For the year ending 2025-12-31, HALO had $20,571K increase in cash & cash equivalents over the period. $644,588K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income | 316,889 |
| Share-based compensation | 51,565 |
| Depreciation and amortization | 11,389 |
| Amortization of intangible assets | 76,662 |
| Amortization of debt discount | 7,506 |
| Accretion of premium on marketable securities, net | 3,296 |
| Realized gain on marketable securities | 171 |
| Loss on disposal of equipment | -2,621 |
| Contingent liability fair value measurement adjustment | 0 |
| Lease payments recognized (deferred) | -951 |
| Induced conversion expense related to 2027 and 2028 convertible notes | 5,477 |
| Deferred income taxes | -634 |
| Acquired in-process research and development expense | 284,887 |
| Impairment of intangible asset | 48,700 |
| Accounts receivable, net and other contract assets | 128,063 |
| Inventories | -2,554 |
| Prepaid expenses and other assets | 32,958 |
| Accounts payable and accrued expenses | 6,211 |
| Net cash provided by operating activities | 651,558 |
| Purchases of marketable securities | 247,355 |
| Proceeds from sales and maturities of marketable securities | 722,248 |
| Acquisition of business, net of cash acquired | 725,965 |
| Acquisition of in-process research and development, net of cash acquired | 287,771 |
| Purchases of property and equipment | 6,970 |
| Net cash used in investing activities | -545,813 |
| Repayments of convertible notes-A2024Convertible Notes | 0 |
| Repayments of convertible notes-A0.25Convertible Senior Notes Due2027 | 595,425 |
| Repayments of convertible notes-A1.00Convertible Senior Notes Due2028 | 250,001 |
| Proceeds from convertible debt-A0.00Convertible Senior Notes Due2031 | 735,000 |
| Proceeds from convertible debt-A0.875Convertible Senior Notes Due2032 | 735,000 |
| Payment for the induced conversion of 2027 and 2028 convertible notes | 5,477 |
| Premium on repayment of convertible notes settled in cash-A0.25Convertible Senior Notes Due2027 | 78,132 |
| Premium on repayment of convertible notes settled in cash-A1.00Convertible Senior Notes Due2028 | 89,833 |
| Purchase of capped calls on 2031 convertible notes-A0.00Convertible Senior Notes Due2031 | 104,025 |
| Purchase of capped calls on 2031 convertible notes-A0.875Convertible Senior Notes Due2032 | 106,800 |
| Payment of debt issuance cost | 4,938 |
| Repurchase of common stock | 342,372 |
| Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement | 21,829 |
| Net cash used in financing activities | -85,174 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 20,571 |
| Cash and cash equivalents at beginning of period | 115,850 |
| Cash and cash equivalents at end of period | 136,421 |
HALOZYME THERAPEUTICS, INC. (HALO)
HALOZYME THERAPEUTICS, INC. (HALO)